دورية أكاديمية
Immunostaining of stromal CD56 cells in ovarian malignancies.
| العنوان: | Immunostaining of stromal CD56 cells in ovarian malignancies. |
|---|---|
| المؤلفون: | Lima CA; Universidade Federal do Triângulo Mineiro, Department of Gynecology and Obstetrics - Uberaba (MG), Brazil., Jammal MP; Universidade Federal do Triângulo Mineiro, Department of Gynecology and Obstetrics - Uberaba (MG), Brazil., Etchebehere RM; Universidade Federal do Triângulo Mineiro, Surgical Pathology Service - Uberaba (MG), Brazil., Murta EFC; Universidade Federal do Triângulo Mineiro, Department of Gynecology and Obstetrics - Uberaba (MG), Brazil., Nomelini RS; Universidade Federal do Triângulo Mineiro, Department of Gynecology and Obstetrics - Uberaba (MG), Brazil. |
| المصدر: | Revista da Associacao Medica Brasileira (1992) [Rev Assoc Med Bras (1992)] 2023 May 15; Vol. 69 (6), pp. e20220992. Date of Electronic Publication: 2023 May 15 (Print Publication: 2023). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Associação Médica Brasileira Country of Publication: Brazil NLM ID: 9308586 Publication Model: eCollection Cited Medium: Internet ISSN: 1806-9282 (Electronic) Linking ISSN: 01044230 NLM ISO Abbreviation: Rev Assoc Med Bras (1992) Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: São Paulo : Associação Médica Brasileira |
| مواضيع طبية MeSH: | Ovarian Neoplasms*/pathology , Carcinoma*/pathology, Female ; Humans ; Prospective Studies ; Prognosis ; Lymphatic Metastasis ; Neoplasm Staging |
| مستخلص: | Objectives: The aim of this study was to evaluate CD56 immunostaining in the stroma of benign and malignant ovarian epithelial neoplasms and associate the CD56 immunostaining with prognostic factors and survival in ovarian cancer. Methods: Patients with ovarian epithelial neoplasia (n=77) were studied with a prospective cohort. The CD56 immunostaining was evaluated in the peritumoral stroma. Two groups were evaluated: benign ovarian neoplasms (n=40) and malignant ovarian neoplasms (n=37). Data were recorded for histological type and grade, International Federation of Gynecology and Obstetrics staging, molecular subtype, and lymph node metastases. Fisher's exact test and Kaplan-Meier survival curves were used, with a significance level of ≤0.05. Results: We found greater CD56 stromal immunostaining in malignant neoplasms when compared to the group of benign neoplasms (p=0.00001). There was no significant difference in relation to the prognostic factors and survival. Conclusion: Malignant ovarian neoplasms showed higher stromal CD56 immunostaining. As the prognostic value of natural killer in ovarian cancer is controversial, knowing the specific function of each cell present both in the tumor tissue and systemically may help guide successful immunotherapies in the near future. |
| References: | BMC Cancer. 2017 Sep 20;17(1):657. (PMID: 28931370) Trends Cancer. 2018 Aug;4(8):517-519. (PMID: 30064659) Cancers (Basel). 2020 Jul 02;12(7):. (PMID: 32630708) Clin Exp Med. 2018 Nov;18(4):547-554. (PMID: 29802567) Clin Med Insights Oncol. 2016 Aug 02;10:71-6. (PMID: 27512342) Clin Cancer Res. 2016 Jun 15;22(12):3005-15. (PMID: 26763251) Front Immunol. 2021 Feb 19;12:616853. (PMID: 33679757) EJC Suppl. 2020 Aug 22;15:56-66. (PMID: 33240443) Cells. 2021 Jul 06;10(7):. (PMID: 34359872) Clin Cancer Res. 2015 Jul 1;21(13):2941-51. (PMID: 25838397) Immunol Invest. 2020 May;49(4):397-405. (PMID: 31298603) Int J Mol Sci. 2020 Apr 28;21(9):. (PMID: 32354198) Oncoimmunology. 2020 Nov 8;9(1):1843247. (PMID: 33224630) Contemp Oncol (Pozn). 2015;19(4):290-9. (PMID: 26557777) J Immunother Cancer. 2021 Mar;9(3):. (PMID: 33722907) Oncotarget. 2018 Oct 5;9(78):34810-34820. (PMID: 30410679) Oncotarget. 2017 Feb 28;8(9):15621-15631. (PMID: 28152503) Cell Cycle. 2010 Jan 15;9(2):260-8. (PMID: 20023378) Immunol Invest. 2020 Jul;49(5):510-521. (PMID: 31755326) CA Cancer J Clin. 2023 Jan;73(1):17-48. (PMID: 36633525) J Obstet Gynaecol. 2020 Apr;40(3):401-405. (PMID: 31476946) Immunol Invest. 2017 Oct;46(7):677-688. (PMID: 28872976) Front Immunol. 2015 Oct 12;6:500. (PMID: 26528284) Am J Surg Pathol. 2008 Jun;32(6):884-90. (PMID: 18425046) Cells. 2020 Mar 06;9(3):. (PMID: 32155738) |
| تواريخ الأحداث: | Date Created: 20230517 Date Completed: 20230518 Latest Revision: 20230522 |
| رمز التحديث: | 20240829 |
| مُعرف محوري في PubMed: | PMC10185054 |
| DOI: | 10.1590/1806-9282.20220992 |
| PMID: | 37194901 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!